Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
- Status
- TERMINATED
- Phase
- PHASE2
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- RECRUITING
- Phase
- PHASE1
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
- Status
- COMPLETED
- Phase
- PHASE1
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2